pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ivonescimab · news · pharmadog
← back to ivonescimab
News mentioning ivonescimab
49
stories
Jul 22, 26
Summit reports two-year survival data for Western patients, though context lacking
endpoints
Jul 15, 26
J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
biopharma dive
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Jun 11, 26
Summit pulls $500M share sale a day after announcing it
biopharma dive
Jun 5, 26
Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?
biopharma dive
Jun 1, 26
STAT+: A turning point for pancreatic cancer patients
stat
Jun 1, 26
STAT+: Servier to buy Edgewise Therapeutics’ muscular dystrophy drug
stat
May 31, 26
STAT+: A standing ovation for RevMed, and caution for Akeso
stat
May 31, 26
Ultra-low doses could bring costly cancer treatments to more patients in poorer countries
stat
May 31, 26
STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug
stat
May 31, 26
STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
stat
May 31, 26
STAT+: For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds
stat
May 31, 26
Akeso, Summit drug extends survival in closely watched lung cancer trial
biopharma dive
May 30, 26
STAT+: BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA
stat
May 8, 26
OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026
onclive
May 7, 26
Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026
onclive
May 1, 26
Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal
biopharma dive
May 1, 26
Summit slips on ivonescimab's apparent interim miss in sign of investor frustration
endpoints
Apr 30, 26
STAT+: What does Akeso’s primo plenary spot say about its survival data?
stat
← prev
page 2 of 2
next →
